Company Overview - Medline is a medical supply company that manufactures and distributes products such as masks, gowns, and lab kits [3] - The company was taken private in 2021 by a consortium of private equity firms, including Blackstone, Carlyle, and Hellman & Friedman, marking the largest leveraged buyout (LBO) post-financial crisis [3][4] IPO Details - The IPO is expected to price tonight and could be one of the largest debuts in the public markets this year, potentially valued at $55 billion, which is over $20 billion higher than the acquisition price by its sponsors [1][4] - The IPO guidance suggests pricing toward the high end of the range, indicating strong investor interest [2] Business Performance - Medline has demonstrated a resilient business model, with net sales growing each year since its inception in the 1960s at a compound annual growth rate (CAGR) of 18% [4] - The company is expected to benefit from secular tailwinds such as an aging population and the consolidation of healthcare providers [5] Growth Strategy - Medline's growth strategy includes acquiring several companies and continuing this trend to enhance its market position [5] - The concentration within Medline's business and its customer base is viewed as both a potential advantage and a risk factor [6] Market Context - The IPO is seen as a critical test for the IPO market, which has a healthy backlog of deals for 2026, and for the private equity industry, which has faced challenges in finding exits for portfolio companies [4]

Core Viewpoint - Medline, a manufacturer of medical and surgical products, is set to launch its initial public offering (IPO) at a price near the upper limit, potentially becoming the largest IPO of the year [1] Group 1 - The company plans to issue 179 million shares [1] - The offering price is set between $26 and $30 per share [1] - If priced at the maximum, the company could raise $5.37 billion [1]

Summary of Key Points Core Viewpoint - The article discusses the recent IPO activities, highlighting that 10 new stocks were listed last week, with 9 of them raising over $100 million each. Group 1: Recent IPOs - JM Group (JMG) raised $15 million by issuing 3.75 million shares at $4 per share [1] - Wealthfront (WLTH) raised $485 million by issuing 34.62 million shares at $14 per share [2] - Lumexa Imaging Holdings (LMRI) raised $463 million by issuing 25 million shares at $18.5 per share [2] - Cardinal Infrastructure (CDNL) raised $242 million by issuing 11.5 million shares at $21 per share [2] - SPACs Bluerock Acquisition (BLRKU), Carbon Capital Partner (KBONU), Meshflow Acquisition (MESHU), Daedalus Special Acquisition (DSACU), ITHAX Acquisition III (ITHAU), and Twelve Seas III (TWLVU) raised $150 million, $300 million, $300 million, $225 million, $200 million, and $150 million respectively [2] Group 2: Upcoming IPOs - Andersen Group Inc., a tax consulting firm, plans to go public on December 17, 2025, on the NYSE under the ticker ANDG, aiming to raise approximately $176 million by issuing 11 million shares at $14 to $16 per share [3][6] - Medline Inc., a leading medical supplies manufacturer, plans to go public on December 17, 2025, on NASDAQ under the ticker MDLN, aiming to raise approximately $5.37 billion by issuing 17.9 million shares at $26 to $30 per share [8][11]

Core Insights - The U.S. IPO market saw four companies go public and six SPACs listed last week, with eight companies filing for IPOs and four for SPACs [1][4]. Group 1: IPO Highlights - Wealthfront (WLTH) priced at the upper end of its range, raising $485 million with a market cap of $2.6 billion, targeting young "digital-first" customers and boasting over 1.3 million paying clients and $88.2 billion in assets by July 2025 [1]. - Lumexa (LMRI) raised $463 million with a market cap of $1.8 billion, operating 184 outpatient imaging centers across 13 states, and has a high leverage ratio of 3.7 times [2]. - Cardinal Infrastructure (CDNL) raised $242 million with a market cap of $769 million, focusing on utility installation services in the Southeastern U.S. with a backlog valued at $646 million [3]. - JM Group (JMG) raised $15 million with a market cap of $79 million, specializing in merchandise sourcing for various retail categories [3]. Group 2: SPAC Highlights - Six SPACs completed pricing last week, including Meshflow Acquisition (MESHU) and Karbon Capital Partners (KBONU), each raising $300 million targeting blockchain infrastructure and energy sectors respectively [4]. - Other SPACs included Daedalus Special Acquisition (DSACU) raising $225 million for consumer-facing AI and technology, and Twelve Seas III (TWLVU) raising $150 million for investments in oil and gas companies outside the U.S. [4]. Group 3: Upcoming IPOs - Medline (MDLN) plans to raise $5 billion at a market cap of $37.3 billion, focusing on medical supplies distribution, facing recent tariff pressures [8]. - Andersen (ANDG) aims to raise $165 million at a market cap of $1.74 billion, providing tax and advisory services with a 15% CAGR since 2003 [8].

Core Viewpoint - Medline is preparing for an IPO on Nasdaq under the ticker "MDLN.US," which is expected to be the largest IPO in the U.S. stock market in 2025 [1] Group 1: IPO Details - Medline plans to issue 179 million shares with a pricing range of $26 to $30 per share, aiming to raise up to $5.37 billion [1] - The target valuation for Medline is set at $55.3 billion [1] Group 2: Company Background - Founded in 1910, Medline is the largest manufacturer and distributor of medical supplies globally, with products including gloves and surgical instruments [1] - The company was privatized in 2021 after being acquired by Blackstone, Carlyle, and Hellman & Friedman for $34 billion [1] Group 3: Financial Performance - For the first nine months of 2025, Medline reported a net profit of $977 million and revenue of $20.6 billion, both showing year-over-year growth [1] - The company has warned that equivalent tariffs will reduce pre-tax net profit by $325 to $375 million in 2025, and by $150 to $200 million in 2026 [1] Group 4: Market Expectations - The market anticipates that Medline will officially begin trading on December 17 [1]

Medline's IPO and Family Wealth - Medline's IPO is anticipated to be a significant event this winter, potentially valued at up to $55 billion, with the Mills family's remaining stake estimated between $6 billion to $7 billion based on share price projections of $26 to $30 per share [1][2] - The Mills family's total net worth is projected to reach at least $20 billion, combining their stake in Medline and previous earnings from a private equity deal that valued the company at $30 billion [2] Company Performance - Under private equity ownership and the leadership of non-family CEO Jim Boyle, Medline has shown growth, achieving sales of $25.5 billion in 2024 and profits of $1.2 billion [4] Surgical Robotics Investments - Dr. Fred Moll, a pioneer in robotic surgery, has invested around $100 million into next-generation surgical robotics startups, aiming to enhance the capabilities of average surgeons through advanced robotic technology [5][6] - The goal of these investments is to improve medical procedures across various fields, including colonoscopies and heart-valve replacements, utilizing AI to refine surgical techniques [6][7] Forbes Top Hospitals List - Forbes has introduced its inaugural Top Hospitals List for 2026, which aims to provide an unbiased, data-driven evaluation of general acute care hospitals in the U.S. [8] - The list was developed in collaboration with Inovalon and various healthcare experts to assist patients and hospital leaders in assessing healthcare quality [9] Freenome's SPAC Deal - Freenome, a company focused on early cancer detection through blood tests, is going public via a SPAC merger valued at $330 million, which includes a $240 million investment from healthcare investors [10] - The company has partnerships with Roche and Exact Sciences and plans to launch multiple tests by 2026 [10]

Core Insights - Medline has filed for an IPO aiming to raise up to $5.37 billion, which would value the company at approximately $55 billion, making it one of the largest public listings in the US for 2025 [1][4] - The company plans to list 179 million shares on the Nasdaq Global Select Market with an expected price range of $26 to $30 per share [1] Company Overview - Medline employs around 43,000 people and reported net revenues exceeding $25 billion in 2024, with net sales of $20.6 billion for the nine months ending September 27, 2025 [2] - The total addressable market for Medline is estimated to be around $375 billion annually, with the US market representing $175 billion of this opportunity [2] Market Opportunity - The company anticipates long-term growth in the US market driven by factors such as an aging population and increasing prevalence of chronic conditions, which are expected to elevate health expenditures [3] - Medline aims to achieve net sales growth through international expansion and ongoing innovation initiatives [3] IPO Context - If successful, Medline's IPO would be the largest in the medtech and broader healthcare sector for 2025, contrasting with the trend of AI-driven medtech IPOs this year [4] - Other notable AI medtech IPOs in 2025 include Beta Bionics and Kestra, raising $204 million and $235 million respectively [5]

Core Viewpoint - Medline Inc., a major U.S. healthcare company focused on medical supplies, is seeking to raise up to $5.37 billion through an IPO, potentially becoming the largest private equity-backed IPO in history and the largest U.S. IPO of the year [1][2]. Company Overview - Medline specializes in the production and distribution of medical supplies such as gloves, isolation gowns, surgical apparel, and examination tables for hospitals and healthcare professionals [4]. - The company was privatized in 2021 in a $34 billion deal led by private equity firms Blackstone, Carlyle Group, and Hellman & Friedman, marking one of the largest leveraged buyouts in financial history [4]. - Medline has a history dating back to 1910 and is one of the largest private manufacturers and distributors of medical and surgical supplies in North America and globally, with annual sales exceeding $20 billion [4]. IPO Details - The company plans to issue 179 million shares at a price range of $26 to $30 per share, with a maximum valuation of $55.3 billion [1][2]. - If priced at the top of the range, the IPO would raise $5.37 billion, surpassing the previous largest U.S. IPO of $1.75 billion by Venture Global Inc. in January [2]. - The IPO filing was submitted after a prolonged U.S. government shutdown that disrupted many companies' IPO plans, with Medline initially expecting to go public in November [2]. Financial Performance - For the nine months ending September 27, Medline reported a net profit of approximately $977 million and total revenue of about $20.6 billion, compared to a net profit of $911 million and revenue of approximately $18.7 billion in the same period the previous year [3]. Investment and Shareholder Structure - The company has secured approximately $2.35 billion in commitments from cornerstone investors, including Baillie Gifford, Capital Group, and Morgan Stanley's Counterpoint Global [5]. - Following the IPO, the Mills family will retain 17.8% of the voting rights, while Blackstone, Carlyle, and Hellman & Friedman will each hold 18% [7]. Market Context - The total amount raised from U.S. IPOs this year (excluding blank-check companies) is approximately $38.7 billion, which is expected to remain below the pre-pandemic average of nearly $50 billion per year [6]. - Major investment banks, including Goldman Sachs, Morgan Stanley, Bank of America, and JPMorgan, are involved in the IPO process, with the expected pricing to occur after market close on December 16 [8].

Group 1 - Medline plans to raise up to $5.37 billion through an IPO, with a target valuation of $55.3 billion, making it potentially the largest IPO in the U.S. for 2025 [1] - The company intends to issue 179 million shares at an estimated price range of $26 to $30 per share [1] - The upcoming IPO is expected to be a significant event in the market, serving as a key indicator of investor sentiment as it approaches 2026 [1] Group 2 - Medline is one of the largest manufacturers and distributors of medical supplies in the U.S., providing surgical and procedural packs, gloves, and protective clothing used in hospitals and nursing homes worldwide [1]

Private equity-backed Medline is aiming to raise as much as $5.37 billion in its initial public offering in the United States, the medical supplies provider said on Monday. ...